Akebia Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Akebia Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2013 to Q3 2024.
  • Akebia Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$20M, a 38.3% decline year-over-year.
  • Akebia Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$46M, a 21.5% increase year-over-year.
  • Akebia Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$51.9M, a 44.9% increase from 2022.
  • Akebia Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$94.2M, a 66.6% increase from 2021.
  • Akebia Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$282M, a 26.7% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$46M -$20M -$5.55M -38.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$40.4M -$8.58M +$2.59M +23.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$43M -$18M +$8.89M +33.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$51.9M $612K +$6.68M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 -$58.6M -$14.5M +$39.6M +73.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$98.2M -$11.2M -$40.6M -138% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$57.6M -$26.9M +$36.6M +57.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$94.2M -$6.07M +$63.8M +91.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$158M -$54.1M +$5.45M +9.15% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$163M $29.4M +$112M Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$276M -$63.5M +$6.07M +8.73% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$282M -$69.9M +$17.1M +19.7% Oct 1, 2021 Dec 31, 2021 10-Q 2023-08-28
Q3 2021 -$299M -$59.5M +$415K +0.69% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$300M -$83M +$92.7M +52.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$392M -$69.6M -$8.83M -14.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$383M -$87M +$7.48M +7.92% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-25
Q3 2020 -$391M -$60M -$5.37M -9.85% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$386M -$176M -$118M -202% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$268M -$60.7M +$11.7M +16.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$280M -$94.5M -$34.4M -57.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$245M -$54.6M -$28.5M -110% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 -$217M -$58.2M -$24.1M -70.7% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 -$193M -$72.4M -$49M -209% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 -$144M -$60.1M -$75.6M -487% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$68M -$26M -$2.91M -12.6% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$65.1M -$34.1M -$12.6M -58.3% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$52.5M -$23.4M +$21.1M +47.4% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$73.7M $15.5M +$53.4M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-26
Q3 2017 -$127M -$23.1M +$13.2M +36.3% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-26
Q2 2017 -$140M -$21.5M +$14.3M +39.9% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-26
Q1 2017 -$154M -$44.5M -$18.7M -72.7% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-26
Q4 2016 -$136M -$37.9M -$18M -90.7% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-12
Q3 2016 -$118M -$36.3M -$16.8M -86.4% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-12
Q2 2016 -$101M -$35.8M -$25.1M -235% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-12
Q1 2016 -$75.8M -$25.8M -$15.1M -141% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-12
Q4 2015 -$60.7M -$19.9M -$9.49M -91.5% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-06
Q3 2015 -$51.2M -$19.5M -$10.1M -108% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-06
Q2 2015 -$41.1M -$10.7M -$3.07M -40.3% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-06
Q1 2015 -$38M -$10.7M -$998K -10.3% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-06
Q4 2014 -$37M -$10.4M -$4.42M -74.4% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-14
Q3 2014 -$32.6M -$9.35M -$5.58M -148% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-14
Q2 2014 -$27M -$7.62M -$4.79M -169% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-14
Q1 2014 -$22.2M -$9.7M -$9.08M -1462% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-14
Q4 2013 -$13.2M -$5.95M Oct 1, 2013 Dec 31, 2013 10-K 2015-03-04
Q3 2013 -$3.77M Jul 1, 2013 Sep 30, 2013 10-K 2015-03-04
Q2 2013 -$2.83M Apr 1, 2013 Jun 30, 2013 10-K 2015-03-04
Q1 2013 -$621K Jan 1, 2013 Mar 31, 2013 10-K 2015-03-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.